Diagnostic Framework in Myelodysplastic Syndromes Management

The Groupe Francophone des Myélodysplasies (GFM) has updated clinical recommendations to optimize myelodysplastic syndromes management. Diagnosing these complex hematologic conditions requires an integrated, stepwise clinical approach. Initially, hematologists evaluate complete blood counts and peripheral blood smears to assess persistent cytopenias and dysplastic cell morphology. Bone marrow aspiration and core biopsy remain mandatory to determine marrow cellularity, identify multilineage dysplasia, and quantify blast counts. Additionally, conventional cytogenetic karyotyping reveals critical structural chromosomal abnormalities, including 5q deletions, monosomy 7, or complex alterations.

Furthermore, advanced molecular biology now serves as an essential pillar of modern diagnostic hematology. Clinicians must perform targeted next-generation sequencing panels to detect recurrent somatic mutations across myeloid genes. For example, identifying SF3B1 alterations delineates specific disease entities, while detecting TP53, RUNX1, or ASXL1 mutations highlights aggressive biology. In chronic myelomonocytic leukemia, persistent monocytosis exceeding one thousand cells per microliter confirms diagnosis. Pathologists must carefully distinguish neoplastic monocytosis from reactive inflammatory responses. Multidisciplinary collaboration between hematopathologists and clinicians ensures accurate diagnostic classification, enabling timely identification of clonal evolution and disease progression.

Surveillance Protocols for CHIP and CCUS Precursor States

The GFM consensus emphasizes structured surveillance for clonal precursor states, specifically clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenias of undetermined significance (CCUS). Although CHIP involves somatic mutations without peripheral cytopenias, CCUS combines clonal mutations with persistent, unexplained hematologic deficits. Notably, longitudinal studies demonstrate that individuals with CCUS face a ten to thirty percent cumulative risk of progression to myelodysplastic syndromes over ten years. Therefore, structured hematologic monitoring protects vulnerable patients from sudden leukemic transformation.

Clinicians must monitor patients through regular complete blood counts every three to six months. In addition, physicians should watch for declining platelets, worsening anemia, or emerging neutropenia. If cytopenias deteriorate, repeat bone marrow evaluation and molecular profiling become necessary. Furthermore, specific high-risk genetic mutations, such as spliceosome alterations and epigenetic regulators, indicate an increased risk of clonal expansion. Beyond hematologic progression, clonal hematopoiesis drives cardiovascular morbidity via chronic inflammatory pathways. Consequently, comprehensive patient care requires collaborative surveillance addressing cardiovascular risk factors alongside hematologic indices. Proactive clinical observation ensures early disease detection before clinical decompensation occurs.

Genomic Risk Stratification Using IPSS-R and IPSS-M Models

Accurate prognostic stratification guides therapeutic decisions in myelodysplastic syndromes. Historically, hematologists relied on the Revised International Prognostic Scoring System (IPSS-R), which assesses cytopenias, blast percentages, and cytogenetic patterns. However, the Molecular International Prognostic Scoring System (IPSS-M) now provides superior predictive power. This updated model combines clinical variables with somatic mutations across thirty-one relevant myeloid genes. As a result, molecular profiling reclassifies nearly half of evaluated patients into more precise risk categories.

Critically, multi-hit TP53 mutations denote an exceptionally adverse prognosis regardless of marrow blast percentages. Similarly, mutations in genes such as FLT3, MLL, and NPM1 predict accelerated progression toward acute myeloid leukemia. Conversely, isolated SF3B1 mutations correlate with favorable clinical outcomes and improved treatment responsiveness. By integrating molecular genetics into baseline evaluations, clinicians avoid undertreating cryptic high-risk disease or overtreating indolent conditions. Furthermore, individualized genomic risk calculations empower physicians to tailor surveillance and therapeutic intensity. Hematologists should routinely calculate IPSS-M scores whenever comprehensive next-generation sequencing is available to optimize clinical trajectory assessments.

Therapeutic Advances in Lower-Risk Myelodysplastic Syndromes

Lower-risk myelodysplastic syndromes primarily manifest as chronic symptomatic anemia, impairing patient functional capacity and independence. Consequently, therapeutic management aims to alleviate transfusion dependence and restore safe hemoglobin concentrations. First-line therapy relies on recombinant erythropoiesis-stimulating agents (ESAs), which deliver meaningful responses in patients with low endogenous erythropoietin levels. Nevertheless, many patients experience secondary treatment failure or lack primary responsiveness.

For individuals with ring sideroblasts or SF3B1 mutations refractory to ESAs, luspatercept represents a major therapeutic breakthrough. This erythroid maturation agent neutralizes select transforming growth factor-beta superfamily ligands, thereby restoring effective late-stage erythropoiesis. In addition, telomerase inhibition with imetelstat offers promising hematologic improvement for transfusion-dependent patients who fail conventional therapies. For individuals harboring isolated 5q deletions, lenalidomide remains the established standard of care, inducing durable transfusion independence and cytogenetic remissions. Clinicians must also provide judicious supportive care, including iron chelation therapy to prevent secondary organ damage from iron overload. Thus, modern targeted biological agents significantly enhance clinical outcomes while sparing patients from debilitating chemotherapy toxicities.

Management of Higher-Risk MDS, CMML, and VEXAS Syndrome

Patients diagnosed with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia require immediate therapeutic intervention to prolong survival and prevent acute transformation. Hypomethylating agents, particularly azacitidine, represent the foundational treatment standard. Azacitidine significantly extends overall survival and delays leukemic evolution. To enhance response rates, investigators combine azacitidine with venetoclax, the targeted BCL-2 inhibitor. Although this combination demonstrates high efficacy, clinicians must manage prolonged, severe myelosuppression with dose adjustments and supportive growth factors.

Additionally, allogeneic hematopoietic stem cell transplantation remains the only curative therapy for fit candidates. Modern transplant protocols utilize reduced-intensity conditioning and post-transplant hypomethylating maintenance to decrease relapse rates. For chronic myelomonocytic leukemia, hydroxyurea controls myeloproliferation, whereas azacitidine treats advanced dysplastic disease. Furthermore, the GFM guidelines address VEXAS syndrome, an autoinflammatory disorder driven by somatic UBA1 mutations. Clinically, VEXAS features relapsing polychondritis, vasculitis, pulmonary infiltrates, and bone marrow vacuolization. Corticosteroids provide initial relief, but steroid-sparing biotherapies and azacitidine offer durable clonal suppression. Close interdisciplinary collaboration optimizes clinical outcomes for these complex, high-risk patients.

Frequently Asked Questions

What role does the IPSS-M score play in clinical decision-making?

The Molecular International Prognostic Scoring System (IPSS-M) integrates clinical parameters, cytogenetics, and somatic gene mutations to assess myelodysplastic syndromes. Unlike older scoring tools, IPSS-M analyzes alterations in thirty-one myeloid genes, including TP53, SF3B1, and ASXL1. Consequently, this model refines risk prediction, reclassifying nearly half of patients into more accurate prognostic tiers. Clinicians use these precise risk scores to distinguish truly indolent disease from aggressive illness, guiding early transplant decisions or targeted interventions.

How should clinicians monitor patients diagnosed with CHIP and CCUS?

Clinicians should establish structured surveillance protocols for clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance. Patients require complete blood counts every three to six months to detect progressive cytopenias or macrocytosis. If blood counts deteriorate, clinicians must perform repeat bone marrow aspiration and molecular sequencing. Furthermore, clinicians should assess cardiovascular health regularly because somatic clonal hematopoiesis significantly increases systemic vascular inflammation, atherogenesis, and thrombosis risks.

What therapies are recommended for VEXAS syndrome according to GFM?

Management of VEXAS syndrome requires addressing systemic inflammation and underlying clonal hematopoiesis driven by somatic UBA1 mutations. Systemic corticosteroids provide rapid symptom relief during acute inflammatory episodes; however, long-term dependence causes significant toxicity. Therefore, the GFM guidelines recommend steroid-sparing biological therapies, including interleukin-1 and interleukin-6 inhibitors. Furthermore, hypomethylating agents like azacitidine effectively target the abnormal UBA1 clone, producing meaningful clinical and hematologic remissions in steroid-refractory patients.

Disclaimer: This content is for informational and educational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. Healthcare professionals must exercise independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Park S et al. [Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome]. Bull Cancer. 2026 Oct 15. doi: undefined. PMID: 42881104.


2. Fenaux P, Haase D, Santini V, et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(2):142-156.


3. Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1(7):EVIDoa2200008.